Measles Vaccine Developer Samuel Katz Dies at 95

He also worked on immunizations against polio, rubella, influenza, and more.

Written byLisa Winter
| 3 min read
Sam Katz looks at camera
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Measles was once a common childhood ailment, claiming millions of lives globally each year. Samuel Katz, one of the primary developers of the attenuated measles vaccine that helped to slash that death toll, died at his home in Chapel Hill, North Carolina, on October 31 at age 95.

Katz was born in New Hampshire on May 29, 1927. According to an obituary from Duke University, he completed a year at Dartmouth College before enlisting in the United States Navy in 1945. Since World War II was nearing its end, he was sent to work in a San Diego hospital. His interest in medicine was piqued, and when he returned to Dartmouth, he completed his undergraduate degree and then a two-year preclinical program in 1950. He attended medical school at Harvard University, graduating in 1952. Katz then stayed in Boston, doing training and fellowships at hospitals around the city.

According to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies